Valuation : Avacta Group Plc

Market Cap 32Cr 44Cr 38Cr 35Cr 60Cr 4.17TCr 61Cr 421.91Cr 162.38Cr 2.12TCr 163.95Cr 160.36Cr 6.72TCr P/E 2026 *
-10.7x
P/E 2027 * -12.4x
Enterprise Value 32Cr 43Cr 37Cr 35Cr 60Cr 4.13TCr 60Cr 417.55Cr 160.7Cr 2.1TCr 162.25Cr 158.71Cr 6.66TCr EV / Sales 2026 *
116x
EV / Sales 2027 * 42.1x
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Avacta Group Plc

Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 60 03/02/2020
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-1.36%+44.08%+102.76% 6.82TCr
+0.51%-3.74%+31.37%+74.94% 6.22TCr
-1.18%+0.47%-12.78%+384.69% 2.78TCr
-1.05%-4.43%+30.56%+10.07% 2.49TCr
-1.76%-6.30%-4.55%-19.75% 2.42TCr
+0.14%-3.60%+14.58%-19.48% 1.94TCr
-1.86%-2.22%+202.03%+353.89% 1.73TCr
-1.94%-4.94%-5.29%+495.65% 1.45TCr
-1.54%-2.88%+52.33%+159.75% 1.42TCr
Average -0.99%-3.30%+39.15%+171.39% 3.03TCr
Weighted average by Cap. -0.61%-3.10%+35.56%+136.87%

Financials

2026 *2027 *
Net sales 27.44L 37.11L 31.92L 30.12L 51.29L 35Cr 51.75L 3.59Cr 1.38Cr 18Cr 1.39Cr 1.36Cr 57Cr 81.18L 1.1Cr 94.44L 89.11L 1.52Cr 104.99Cr 1.53Cr 11Cr 4.08Cr 53Cr 4.12Cr 4.03Cr 169.15Cr
Net income -2.89Cr -3.91Cr -3.36Cr -3.17Cr -5.41Cr -374.01Cr -5.45Cr -38Cr -15Cr -189.7Cr -15Cr -14Cr -602.55Cr -2.36Cr -3.2Cr -2.75Cr -2.59Cr -4.42Cr -305.71Cr -4.46Cr -31Cr -12Cr -155.06Cr -12Cr -12Cr -492.52Cr
Net Debt -33.35L -45.11L -38.8L -36.61L -62.34L -43Cr -62.9L -4.36Cr -1.68Cr -22Cr -1.69Cr -1.66Cr -69Cr 1.9Cr 2.57Cr 2.21Cr 2.08Cr 3.55Cr 245.66Cr 3.58Cr 25Cr 9.56Cr 124.6Cr 9.65Cr 9.44Cr 395.77Cr
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!